drugset / Trial / NCT00600964
A Phase I/II Study of GX15-070MS in Untreated CLL
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This protocol is being run to determine the best phase II dose and schedule of obatoclax in patients with previously untreated CLL.
Timeline
- Start
- 2004-09
- Primary completion
- 2006-01
- Completion
- 2006-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Obatoclax | Small molecule | 3.5 mg/m2 | Intravenous |
| Subject | Obatoclax | Small molecule | 14 mg/m2 | Intravenous |
| Subject | Obatoclax | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Obatoclax | Small molecule | 28 mg/m2 | Intravenous |
| Subject | Obatoclax | Small molecule | 40 mg/m2 | Intravenous |